Dermira is bringing biotech ingenuity to medical dermatology, delivering advanced treatments to the millions of patients with chronic skin conditions.
Location: United States, California, Redwood City
Total raised: $128M
Founded date: 2010
Investors 5
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Aisling Ca... | aislingcap... |
| - | Canaan Par... | canaan.com |
| - | Bay City C... | baycitycap... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.08.2014 | Series C | $51M | - |
| 11.06.2013 | Series B | $35M | - |
| 20.10.2011 | Series A | $42M | - |
Mentions in press and media 20
| Date | Title | Description |
| 13.01.2020 | Eli Lilly acquires skin disease-focused Dermira in $1.1B deal | Dermira has one approved product, Qbrexza (glycopyrronium), a medicated cloth used to treat primary axillary hyperhidrosis, or excessive underarm sweating. The lead product candidate in its pipeline is lebrikizumab, a monoclonal antibody in... |
| 12.10.2018 | Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis | Full article from Dermira MENLO PARK, Calif., Sept. 5, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the milli... |
| 13.09.2017 | Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients | MENLO PARK, Calif., Sept. 13, 2017 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living wit... |
| 10.05.2016 | Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 | Menlo Park, CA — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today annou... |
| 09.06.2015 | Dermira’s Phase 2a Trial Data Presented at the World Congress of Dermatology Meeting | Menlo Park, CA — Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its ... |
| 09.04.2015 | Dermira Doses First Patient in DRM01 Phase 2b Acne Trial | Menlo Park, CA — Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the initial dosing of the first patient in ... |
| 23.03.2015 | Dermira Presents Clinical Data for Its DRM01 Acne Program at Dermatology Meeting | Menlo Park, CA — Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its ... |
| 08.01.2015 | Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis | Menlo Park, CA, and Brussels, Belgium — Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (Nasdaq:DERM), and UCB, a globa... |
| 17.10.2014 | Report: Funding in runup to biotech and medical device IPOs boosts Q3 investment | There were 23 venture-backed IPOs in the third quarter and 18 of them were biotech and medical device IPOs. One was the first company to commercialize a bionic eye. Second Sight Medical raised about $32 million in an IPO in August. When it ... |
| 03.10.2014 | Dermira Prices Initial Public Offering | REDWOOD CITY, Calif., October 2, 2014 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced... |
Show more